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 The status of research, development and application of genetic technology in the US has been reflected 
through efforts and accomplishments in numerous fields including research, medicine, industrial biotechnology 
and agriculture in the past decades. In the area of medicine, the field of therapeutic purposes on human is the 
pioneer, in which gene therapy is attempted to carry out in various clinical trials. Diagnostic applications of 
human diseases which focus primarily on infectious diseases, cancer, pharmacogenomics and screening for 
inherited diseases by using molecular techniques related to PCR, next generation sequencing are followed. In 
addition, preparatory studies on human cells utilizing CRISPR/Cas9 genome editing technology have been 
undertaken in hopes of finding new treatments for cancer and rare form of eye disorder. In the field of 
agriculture, many large companies in the US have been developing varieties of genetically modified crops with 
traits of herbicide tolerance, insect resistance, drought resistance and nutrition enhancement. Among the 
biotech crops, proportion of planted acres of genetically engineered soybean, corn and cotton were increased 
rapidly and forecasted to expand in the coming years. Studies on generating genetically modified animals and 
fisheries have also been concentrated in order to not only resist diseases, enhance nutrition, but also provide 
pharmaceutical compounds. Application of new gene editing techniques such as CRISPR/Cas9 on plants and 
animals help biotech products have more opportunities to be approved for commercial sale in the US market. 
In general, although the research and application of genetic engineering in the US has outstripped worldwide, 
numerous obstacles are still encountered due to serious ethical regulations and controversy regarding to human 
health and environment. The US government continues to establish suitable policies and invest in science and 
technology to improve the quality of human life. 
Keywords: Genetic technology, PCR, next generation sequencing, CRISPR/Cas9 genome editing, gene 
therapy, genetically modified crops 
INTRODUCTION 
 The United States of America is a leading 
country in biotechnology research and application in 
the world. In 2016, revenue from commercial 
activities of public companies in the US biotech 
sector reached US$ 112.2 billion. Research and 
development (R&D) expenses jumped 14% over the 
year 2015 and accounted for about US$ 38.8 billion. 
Large biotech companies such as Amgen, Biogen, 
Celgene, Regeneron Pharmaceuticals, along with 
Gilead represented for nearly three quarters of the 
US biotech revenue and more than half of total 
biotech revenue worldwide (http://www.ey.com). 
Therapeutic purposes on human is the pioneer and 
the largest major area in biotechnology. With new 
developed genetic technologies, the diagnostic 
applications of human diseases are expected to grow 
quickly, stand in the second place after therapeutic 
field, and focus primarily on infectious diseases, 
cancer, pharmacogenomics and screening for 
inherited diseases. The agricultural sector has made a 
rapid progress with lots of practical applications 
although it comes behind the two sectors outlined 
above. Genetically modified (GM) maize acres 
continue to grow rapidly in the US, while GM 
soybean acres are anticipated to expand in the 
coming years. Studies using genetic technology on 
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animals and fisheries have also been concentrated in 
order to increase biotech products and to solve 
problems of environmental pollution. This review 
summarizes the current status of research, 
development and application of genetic engineering 
in the field of medicine and agriculture in the US, 
thereby assessing the level of technology that the US 
has achieved over the past few years. 
RESEARCH AND APPLICATION OF GENETIC 
ENGINEERING IN THE FIELD OF MEDICINE 
Genetic technology in basic medical research 
related to human genome 
 The Human Genome Project was an 
international scientific research project that formally 
launched in 1990 by the US Department of Energy 
and the National Institutes of Health (NIH) and was 
headed by James D. Watson. The technique used to 
conduct the study was primarily hierarchical shotgun 
sequencing method which shears DNA randomly 
into numerous large chunks and clones into a 
bacterial artificial chromosomes host (International 
Human Genome Sequencing Consortium, 2001; 
Venter et al., 2001). The results of whole genome 
sequencing revealed that only 1.1% of the genome is 
spanned by exons, whereas 24% is in introns, with 
75% of the genome being intergenic DNA (Venter et 
al., 2001). Although it was obviously restricted in 
applying complicated technology, the 
accomplishment of this project have opened a new 
era for developing genetic engineering in order to 
improve DNA identification and analysis methods. 
In addition, significant medical benefits have been 
contributed including the discovery of 1800 disease 
genes, over 2000 genetic tests for identifying risks of 
human health problems, and many relevant biotech 
products applied in clinical trials. In 2002, the 
International HapMap Project which developed a 
haplotype map (HapMap) of the human genome 
aimed to map and understand the common patterns 
of human genetic variation. Thenceforth, the project 
could accelerate an elicitation of genetic variants 
affecting health, disease and individual responses to 
pharmacological agents (Thorisson et al., 2005). In 
2010, the Phase III of the HapMap project was 
claimed with approximate 1.6 million single 
nucleotide polymorphism (SNPs) were genotyped 
from 1184 individuals of 11 global ancestry groups, 
and ten 100-kilobase regions of 692 individuals were 
sequenced (International HapMap 3 Consortium, 
2010). The database of this project has been the 
largest survey of human genetic variant and 
contributed to find SNPs in any region of interest 
and their allele frequencies, or to identify genes 
related to common human diseases. Nowadays, since 
the next generation sequencing (NGS) technology 
has been improved and developed rapidly, whole 
genome sequencing (WGS) of an individual is no 
longer a difficult challenge for scientific research. 
NGS technology uses parallel analyses to sequence 
multiple genes of interest, whole exome sequencing 
(WES) or WGS of variants in a variety of rare and 
complex disorders. In addition, due to a sharp 
reduction in the cost of WES or WGS, recent studies 
of comparative genomics identified the causes of 
rare diseases such as Kabuki and Miller syndromes. 
In comparison with the WGS method, WES was 
verified to be a quick and accurate approach for 
some of the Mendelian disorder (Worthey et al., 
2011). It is explained that WES successfully 
captured 95% of the coding regions with a minimal 
coverage of 20X, in which 85% mutations of 
Mendelian disorder and SNPs across the genome 
were detected (Rabbani et al., 2014). Furthermore, 
WES is improved to analyze more efficiently by 
sequencing whole exome of patient and his parents 
(trio sequencing) or other family members, 
allowing to detect de novo mutations which are the 
cause of many severe early-onset disease (Katsanis, 
Katsanis, 2013).  
 A new ambitious initiative, The Cancer Genome 
Atlas (TCGA), was suggested with a comprehensive 
and coordinated effort to accelerate understanding of 
the molecular basis of cancer. The mission of TCGA 
project is to identify and to catalogue all the genetic 
abnormalities found in 50 different types of cancer. 
The project applies high-throughput genome analysis 
techniques and bioinformatics to generate publicly 
available data source, to improve diagnostic methods, 
treatment standards, and to develop strategies for 
cancer prevention (Chin et al., 2011). TCGA 
completed genomic characterization of 33 cancer 
types that have poor prognosis and affect public 
health, including 10 rare cancers. The targeted types 
of cancer for this study were comprised of breast, 
central nervous system, endocrine, gastrointestinal, 
gynecologic, head and neck, hematologic, skin, soft 
tissue, thoracic and urologic cancers 
(https://cancergenome.nih.gov/cancersselected). 
Researchers believed the project’s accomplishment 
would expand the comprehension of molecular 
cancer, characterize the genetic traits of tumors in 
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order to become therapeutic or drug targets. These 
basic genetic studies will be the foundation for 
personalized analyses based on individual genome in 
precision medicine to provide appropriate treatment 
for genetic diseases and cancer. With the goal of 
improving personalized medicine, the largest cohort 
study for President Obama’s Precision Medicine 
Initiative (PMI) has been launched since 2015. 
Thenceforth, one million volunteers were recruited 
and sequenced their whole genomes. The result of 
this project will be a revolutionary approach for 
studying a large number of diseases, providing 
predictions of risk disease better, and improving the 
diagnosis, prevention and treatment that takes into 
account individual differences in lifestyle, 
environment, and biology. Through advances in 
research, technology, and policies that empower 
patients, the PMI will enable a new era of medicine 
in which researchers, health care providers, and 
patients work together to develop individualized care. 
 Recent advances in the development of gene 
editing technologies based on programmable 
nuclease enzymes have significantly ameliorated the 
implementation of accurate modifications in 
eukaryotic genomes. These techniques which include 
meganuclease and its derivatives, zinc finger 
nucleases (ZFNs), transcription activator-like 
effector nucleases (TALENs), and CRISPR/Cas9 
open the potential for genome editing therapy in 
treating disease cells and tissues, removing or 
modifying harmful mutations, introducing 
protectable mutations, supplementing therapeutic 
genes, or disrupting the viral DNA. In the US, many 
studies using CRISPR/Cas9 technology can alter 
gain-of-function mutations (such as the SOD1 G93A 
mutation in amyotrophic lateral sclerosis, and point 
mutation p.A673T of APP gene in Alzheimers 
disease) or loss-of-function mutations (mutations in 
Tay-Sachs disease, for instance) to restore normal 
function (Cox et al., 2015). In addition, this genome 
editing technique was successfully demonstrated in 
treating tyrosinemia disease due to Fah mutations in 
hepatocytes (Yin et al., 2014). Experiments on 
mouse models of human genetic disease generated 
permanent alteration which was able to disrupt the 
PCSK9 gene in vivo with high efficiency (> 50%), 
decreased plasma PCSK9 levels, increased hepatic 
low-density lipoprotein receptor levels and reduced 
plasma cholesterol levels (by 35 - 40%), leading in 
preventing cardiovascular disease (Ding et al., 2014). 
However, the CRISPR/Cas9 system has a 
disadvantage in limiting the precise target site that 
usually causes unwanted genomic modifications. 
Numerous studies evaluating the specificity of this 
type of genetic modification system in many cell 
lineages indicated that the sequences which are 
highly homologous with target sites are also mutated 
considerably. Furthermore, as DNA repair systems 
may not integrate DNA fragment into the genome, 
target alleles are possible to carry additional variants 
such as deletions, partial or multiple integrations of 
the targeting vector, and even duplications (Li et al., 
2015; Pavlovic et al., 2016). To reduce the ratio of 
off-target mutagenic effects, several research groups 
proposed solutions to improve the specificity of Cas9. 
One of them was to create a mutation in one of two 
Cas9’s nuclease regions to form the Cas9 nickase 
(nCas9) that can only break single-stranded DNA 
(Mali et al., 2013). Therefore, it is capable of 
generating a double-stranded DNA break by 
producing two separate single-stranded DNA breaks 
on both complementary DNA target strands using 
two different guide RNAs. Additionally, this manner 
was relevant to enhance specificity and decrease the 
formation of indels at off-target sites (Ran et al., 
2013; Shen et al., 2014). The other methods in which 
guide RNA fragment is shorter than 20 nucleotides 
(Fu et al., 2014) or RNA-guided FokI nuclease is 
based on a combination of inactive FokI and Cas9 
nuclease regions (Cas9 mutated in both nuclease 
regions) (Guilinger et al., 2014; Tsai et al., 2014) 
were demonstrated to improve considerably 
efficiencies of on-target genome editing. Another 
approach involving in manipulations of 
Streptococcus pyogenes Cas9 (SpCas9) to obtain the 
SpCas9-HF1 variant was also performed the accurate 
interaction with target genes in multiple human cell 
lines with more than 85% single-guide RNAs 
(sgRNAs) (Kleinstiver et al., 2016). The application 
of CRISPR/Cas9 technology to human cell trials has 
been approved by the NIH in June 2016. In 2017, the 
study based on the first human-based trial using the 
CRISPR/Cas9 technique by Chinese scientists was 
carried out by scientists from the University of 
Pennsylvania. Specifically, T cells were obtained 
from 18 patients with advanced stages of myeloma, 
sarcoma and melanoma. CRISPR was then used to 
remove the gene encoding PD-1 protein, which 
functions to regulate the immune response of T cells 
to prevent it from attacking healthy cells, and the 
two genes that encode T cell receptors which direct 
T cells to target on tumors instead of exotic DNA or 
viruses. Furthermore, these T cells were also inserted 
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the NY-ESO-1 receptor-encoding gene which is 
capable of detecting NY-ESO-1 protein in certain 
tumors via viral vectors. Ultimately, these edited T 
cells were cloned and infused into the patient's blood 
in the hope that they can attack and eliminate cancer 
(Reardon, 2016). The US researchers assume that the 
combination of the two technologies can help cancer 
treatment more effectively. On the other hand, this 
first CRISPR clinical trial implemented also aimed 
to demonstrate that the technique is safe for human 
since there are many concerns about the accuracy of 
breakage site in target gene. The generation of 
cancer causing mutations is hypothesized to turn T 
cells into cancerous cells, however, no abnormalities 
have been observed during modified T cells have 
been cultured. If this test is safe, the US will apply 
CRISPR in a clinical trial for a rare form of eye 
disorder. 
Application of genetic technology in medical 
diagnosis  
 The US is expected to be the largest molecular 
diagnostics market with a growth is projected to 
reach US$ 4.2 billion by 2023. At the present, the 
molecular diagnostics forms a small segment in a 
global market but it is determined as the fastest-
growing market. The major factors driving this 
market are an augment in the incidence of chronic 
disorders, aging population and a trend toward 
personalized medicine. Therefore, molecular 
diagnostic tests have become a powerful tool for 
detecting rapidly and identifying disease-associated 
DNA or RNA sequences precisely. Current clinical 
trial applications concentrate on the screening and 
detecting infectious diseases, genetic disorders and 
cancer at the early stage. Based on technology, PCR 
and its advanced variants are expected to command 
the largest share, accounting for more than 75%. 
NGS, microarray and fluorescence in situ 
hybridization (FISH) methods that are applicable in 
many cases are following.   
 For viral infectious diseases, the LAMP and 
NASBA assays yielded 100% sensitivity for 
detecting influenza A virus subtypes H1N1 and 
H3N2 (Poon et al., 2005), and H5N1 (Moore et al., 
2004), respectively, while influenza B virus could be 
detected with a sensitivity up to 97.9% by SAMBA 
technique (Wu et al., 2010). There are currently 21 
tests which have been approved by the US Food and 
Drug Administration (FDA) for influenza diagnosis 
(Vemula et al., 2016). Besides, issues about 
determination of HIV-1 infection and assessment of 
HIV/AIDS progression has also been solved. 
Specifically, the US clinical microbiology 
researchers combined viral RNA quantitative assay 
with serological testing. HIV-1 infection usually 
results in prolonged survival of the virus. Thus, HIV-
1 RNA is commonly determined by RT-PCR, 
NASBA or branched chain DNA (bDNA). Several 
companies released tests approved by FDA to 
monitor HIV-1-infected patients. The typical 
COBAS AmpliPrep/COBAS TaqMan HIV-1 (Roche 
Diagnostics, Indianapolis, IN, USA) test is proved to 
be capable of quantitating HIV-1 viral load with 
limited detection in the range of 50-1,000,000 
copies/ml (Scott et al., 2009). The quantification of 
HIV-1 RNA also contributed to assessing HIV-1-
transmitted drug resistance (TDR) (Shafer, 2002). 
Currently, two commercial assays are available for 
HIV-1 genotyping: (i) the TruGene HIV-1 
Genotyping Kit and OpenGene DNA Sequencing 
System (Siemens Healthcare Diagnostics, Tarrytown, 
NY, USA); and (ii) the ViroSeq HIV-1 Genotyping 
System (Abbott Molecular). Both systems work well 
for the HIV-1 B subtype circulating in North 
America (Tang, Ou, 2012). Virus quantification tests 
are also used to screen and measure the drug 
response of patients with hepatitis B virus (HBV) or 
hepatitis C virus (HCV) infection. Nowadays, there 
are a lots of commercial HBV DNA quantification 
kits available with high sensitivity in blood or blood 
products. Two archetypal kits are VERSANT HBV 
DNA 3.0 (Bayer Healthcare LLC, NY, USA) based 
on bDNA and COBAS AmPliprep (Roche 
Diagnostics, NJ, USA) based on real-time PCR with 
the limit detection threshold 2 × 103 copies/ml (Yao 
et al., 2004) and 6 IU/ml (Ronsin et al., 2006), 
respectively. For bacterial infectious diseases, high-
sensitivity PCR method have replaced conventional 
methods such as direct fluorescent-antibody and 
culture for detecting Chlamydia trachomatis and 
Neisseria gonorrheae in vaginal specimens (Cook et 
al., 2005). Application of multiplex-PCR allowed 
to identify Neisseria meningitidis, Streptococcus 
pneumoniae and Haemophilus influenzae type B 
which accounts for 90% cases of bacterial 
meningitis (Tzanakaki et al., 2005). Besides the 
burden of infectious disease, microbial resistance 
is a serious problem. Therefore, rapid detection 
and report of antibiotic-resistant strains such as 
Methicillin-resistant Staphylococcus aureus 
(MRSA), Vancomycin-resistant enterococci 
(VRE), multi-drug-resistant tuberculosis (MDR-
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TB) are a challenge for clinical microbiology 
laboratory. In the US, although doctors have 
coped with MDR-TB for many years (especially 
in New York, Miami, and Los Angeles), some 
MDR-TB strains became resistant to the second-
line agents such as aminoglycosides, 
polypeptides, fluorquinolones, thioamides, 
cycloserine and para-aminosalicylic acid. 
Nevertheless, thanks to the development of 
technology, pyrosequencing technique enabled to 
evaluate mycobacteria species, their drugs 
resistance, and SNP sites to distinguish the 
genotypes of Mycobacterium tuberculosis rapidly. 
 Based on database of the NIH Genetic Testing 
Registry, there are currently more than 5800 genetic 
diseases in which diagnostic tests have been 
developed and provided by hundreds of laboratories 
in the US (http://www.ncbi.nlm.nih.gov/gtr/). For 
detecting point mutations and small variants, 
bidirectional Sanger sequencing has been considered 
as the “gold standard” in clinical genetic testing for 
the past decade. Sequencing the gene TCOF1 
allowed to identify up to 90% of mutations in 
patients with Treacher Collins syndrome (Katsanis, 
Jabs, 2012), or focally sequencing only the FGFR2 
gene could confirm or rule out a diagnosis of Apert’s 
syndrome with fairly low cost (Robin et al., 2011). 
The Sanger sequencing, however, is impossible to 
detect genomic structural variation. Thus, this 
method alone cannot diagnose some genetic 
disorders sufficiently. The DNA microarray 
technology hereby has become an effective tool for 
analyzing the expression of thousands of genes 
simultaneously. In the diagnosis of genetic disorders, 
using microarray can achieve results quickly and 
precisely through detection of chromosomal 
abnormality, investigation of mutation, screening 
and identification of SNP and post-translational 
variation. Xu and colleagues used microarray to 
analyze CFTR-regulated genes in cystic fibrosis (Xu 
et al., 2003). However, this approach is more 
advantageous in prenatal and cancer diagnosis. 
Chromosomal microarray analysis (CMA) was used 
extensively through a trial proceeded at 29 centers 
funded by NIH. The study demonstrated that the 
microarray successfully analyzed for 98.8% of 
embryonic samples, of which 87.9% of the samples 
were directly used without culturing. On the other 
hand, the CMA detected significant difference in 
1.7% of pregnant cases with normal karyotype, and 
6% of pregnancies who have structural abnormalities 
involved in genomic fragment deletion/duplication 
(Wapner et al., 2012; Hillman et al., 2013). In cancer 
screening, the microarray benefits researchers 
because it permits to test a large numbers of genetic 
samples, to identify SNPs and mutations, to classify 
tumors, to determine target genes of tumor 
suppressors, biomarkers of cancer, genes regarding 
to drug resistance, and to find out new specific drug 
simultaneously. An array-based comparative 
genomic hybridization (aCGH) technique was used 
to map abnormal genes in a variety of tumors 
including large B cell lymphoma (Alizadeh et al., 
2000), breast cancer (West et al., 2001), bladder 
cancer (Veltman et al., 2003), fallopian tube 
carcinoma (Snijders et al., 2003), brain cancer 
(Mischel et al., 2004) ... In addition, the microarray 
is also utilized to analyze the CpG island 
methylation status in the promoter regions which are 
inactivated even in the presence of transcription 
factors, for instance in ovarian cancer (Wei et al., 
2006). 
 Although NGS technology has been widely used 
in the field of cancer research, the application of 
NGS in clinical molecular diagnostics of cancer has 
been proceeded recently (Gagan, Van Allen, 2015; 
Corless, 2016). The database from large-scale 
projects of International Cancer Genome Consortium 
(ICGC) and TCGA which recruited and analyzed 
thousands of tumors facilitated to generate 
comprehensive catalogues of genomic abnormalities 
(somatic mutations, abnormal expression of genes, 
epigenetic modifications) from different cancer types 
and/or subtypes. In breast cancer, for instance, many 
studies indicated that NGS is suitable for detecting 
point mutations and indels in the BRCA1/BRCA2 
gene. In addition, when examining 25 genes that are 
associated with a genetic predisposition to breast 
cancer, mutations were identified in 16 genes with 
high frequency such as BRCA1, BRCA2, CHEK2, 
ATM and PALB2 genes, of which 4.3% of cases 
mutated on non-BRCA1/BRCA2 genes (Tung et al., 
2015). This technology was also applied for clinical 
diagnosis of 310 colorectal cancer specimens. As the 
results, mutations were detected in the KRAS gene, 
of which 17% occurred in codons 12 and 13, and in 
the PIK3CA gene with 48% in codons 542, 545 and 
1047. At the same time, the rate of formation of the 
resistant mutants for anti-EGFR therapy increased 
from 40% to 47%, 48%, 58% and 59% when 
examining mutations only in exon 2 of KRAS gene, 
in exons 2 - 4 of the KRAS gene, exon 2 - 4 of both 
KRAS and NRAS gene, additional codon 600 of the 
BRAF gene and exon 20 of the PIK3CA gene (Haley 
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et al., 2015). This suggested that NGS is a powerful 
tool for detecting mutations in clinical laboratories 
with high analytical sensitivity and a wide range of 
assessment which allows to identify numerous 
mutations simultaneously and quantify allele 
frequency of mutation in order to predict tumor 
heterogeneity and allelic imbalance. 
Application of genetic technology in treatment of 
human diseases 
 Gene therapy has become the representative 
application of genetic technology in treatment. The 
US has been at the forefront of the gene therapy 
research and implement gene therapy on human to 
cure adenosine deaminase (ADA) deficiency due to a 
lack of the enzyme ADA, resulting in severe 
combined immunodeficiency (SCID). Basically, 
gene therapy is defined as a method that treats or 
reduces a disease by transferring gene, gene 
fragment, or oligonucleotide into patient cells, 
causing genetic modification in patient cells 
(Strachan, Read, 1999). Gene therapy can be 
performed in two manners in vivo or ex vivo. In the 
in vivo gene therapy, target cells are approached 
directly by microinjection or biopsy. Gene transfer 
can be accomplished by viral or non-viral vectors, in 
which recombinant viruses are manipulated to carry 
tissue-specific promoters. On the other hand, target 
cells are selected from the tumor, then cultured in 
suitable microenvironment in the ex vivo gene 
therapy. Afterward, cells are genetically modified by 
inserting a new gene into their genome and turned 
back to the patient's body. 
 For anticancer gene therapy, initial efforts to 
inactivate oncogenes and replace inactive tumor 
suppressor genes have been unsuccessful. 
Subsequently, new approaches have been developed 
to transfer genes directly into target cells to change 
temporarily or permanently their phenotypes (Miller, 
1992). Target cells may be normal cells, cancer cells, 
immune cells or pluripotent stem cells. Once the 
gene is transferred to a cancer cell, it can support the 
process of apoptosis or recover the healthy cellular 
function. Meanwhile, for normal cells, transgene can 
protect them from drug-induced toxicity or activate 
immune cells to eliminate cancer cells 
(Weichselbaum, Kufe, 1997). 
 Hitherto, the US accounts for 62.9% of clinical 
trials of gene therapy in the world with 1550 trials 
(Deng et al., 2017). Two-thirds of these tests focused 
on cancer treatment. Trial reports presented that gene 
therapy is beneficial for many genetic disorders such 
as Alzheimer's disease, retinopathy due to mutation 
of RPE65 gene, cystic fibrosis, hemophilia, HIV, 
Huntington's disease, muscular dystrophy, 
Parkinson's disease, SCID and many types of cancer 
(http://www.genetherapynet.com/clinicaltrialsgov
.html). Some of the drugs were approved 
commercially for cancer gene therapy including 
ONYX-15 (Onyx Pharmaceuticals) to cure head 
and neck cancer (Chiocca et al., 2004), HPV 
vaccine (Gardasil) (Merck Sharp & Dohme) to 
prevent cervical cancer (Block et al., 2006) and 
modified dendritic cells known as sipuleucel-T 
(ProvengeTM, Dendreon Corporation, Seattle, 
WA, USA) to treat metastatic castrate-resistant 
prostate cancer (Kantoff et al., 2010; Pieczonka 
et al., 2015). Due to a dramatically high 
prevalence rate of cancer in the US, the gene 
therapy segment is anticipated to grow 
substantially in the cancer therapeutics market. 
According to economic experts, the US gene 
therapy industry contributed over 95% of the 
market share of the North American cancer 
therapeutics market in 2015 (around US$ 235 
million), and is expected to grow to 20.9% in the 
next 7 years. Furthermore, government funding 
for cancer research programs and beneficial plans 
for cancer screening program is believed to 
generate profitable opportunities for the cancer 
gene therapy market and facilitate new gene 
therapies. 
Application of genetic technology in disease 
prevention 
 Vaccine was initially developed on an 
experimental basis, primarily based on the reduction 
or inactivation of the pathogen. However, advances 
in immunology, molecular biology, biochemistry, 
genomics and proteomics provided new insights into 
immunization. With the rapid development of 
science and technology, the US has studied and 
applied a variety of modern genetic techniques in 
vaccine technology to produce numerous vaccines 
for specific immune responses to many new and 
urgent diseases. The usage of WGS of 
microorganisms and bioinformatics analysis for 
vaccine design is a relatively new approach in 
detecting antigen, inducing neutralization of humoral 
immune responses and generating T cell vaccines. 
This technology includes following steps: 1) 
Identification of subjects with broadly neutralizing 
antibodies in serum (Simek et al., 2009); 2) 
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Identification of broadly neutralizing monoclonal 
antibodies (bnAbs) from these subjects by single-cell 
technique of memory B cell with or without antigen 
selection and cloning heavy chain and light chain to 
the IgG vector; 3) Determination of the crystal 
structure of these bnAbs’ binding sites by 
crystallization method (Scheid et al., 2011; Burton et 
al., 2012; Kwong, Mascola, 2012); and 4) 
Mimicking the binding sites of bnAbs on protein or 
vector which acts as the molecular basis for the 
immunogenicity to create the bnAbs (Burton et al., 
2012; Kwong, Mascola, 2012). Indeed, pathogens 
with highly antigenic variation such as HIV (Burton, 
2002), HCV (Law et al., 2008) and influenza (Ekiert 
et al., 2011) are suitable candidates for designing 
antigen by this reverse vaccinology. The first success 
was achieved on respiratory syncytial virus (RSV), 
in which immune genes were mimically designed as 
the binding site of an RSV-neutralizing monoclonal 
antibody and generate specific RSV-neutralizing 
antibody in monkey (Schief, 2012).  
 Recently, some of vaccines applied by chimeric 
antigen receptors (CARs) technology have been 
proved to be able to prevent many cancers. The 
researchers designed a lentiviral vector which 
expressed specific CAR for CD19 antigen of B cell, 
in combination with CD137 and CD3-zeta signaling 
region. It could proliferate and eliminate abnormal 
white blood cells from patients with acute lymphoid 
leukemia (Grupp et al., 2013) and chronic lymphoid 
leukemia (Porter et al., 2011). DNA vaccine studies 
have also been performed on animal models to 
enhance the humoral and cell-mediated immune 
responses against pathogens and tumor antigens. In 
comparison with other cancer vaccines, DNA 
vaccines are well tolerated, safe, low cost, easy to 
produce and preserve and have a high potential for 
stimulating immune system of the body. Besides, 
new strategies have been developed to increase the 
efficiency of transferring gene and improve the 
effectiveness of DNA vaccines. Many studies 
demonstrated that the simultaneous distribution of 
plasmids encoding cytokines, chemokines or 
costimulatory molecules could augment the immune 
response. Unlike traditional adjuvants that can 
trigger nonspecific inflammatory response, 
molecular adjuvants can regulate adaptive immune 
responses. For instance, co-distribution of interleukin 
(IL) 12 and IL-28B enhanced antigen-specific CD8+ 
T cell responses, and also increased cytotoxic T 
cells’ ability to kill target cells (Morrow et al., 2010a, 
2010b). Injection of plasmid DNA encoding Melan-
A antigen (MART-1) and tyrosinase in stage IV 
melanoma patients detected immunogenicity of 
Melan-A/MART-1 (Weber et al., 2008). The NY-
ESO-1 DNA vaccine was tested in prostate cancer 
patients and indicated that 93% of patients who were 
unrecognized any immune response previously 
responded to both antigen-specific CD8+ and CD4+ 
T cells (Gnjatic et al., 2009). A phase I clinical trial 
of a Mammaglobin-A (Mam-A) cDNA vaccination 
was shown the ability of inducing Mam-A-specific 
CD8+ T cell-mediated immune response in patients 
with metastatic breast cancer. Moreover, CD4+ T 
cells were also activated and such T-helper cells 
produced cytokines switching IL-10 to INF-γ and 
induced preferential lysis of human breast cancer 
cells expressing Mam-A protein. (Tiriveedhi et al., 
2013). Even though a lots of studies aiming to 
improve the immunity and antitumor potential of 
DNA vaccines, DNA vaccines still need to be 
combined with other cancer therapy to control and 
eliminate tumors completely. 
GENETIC ENGINEERING IN AGRICULTURE 
Development of genetically modified crops 
 In the field of agricultural biotechnology, the US 
was the leader in commercializing biotech crops 
since 1996. Afterwards, the GM planted area has 
grown rapidly yearly and reached 72.92 million 
hectares by 2016 with many types of crops such as 
maize, soybean, cotton, rapeseed, alfalfa, papaya and 
squash (Table 1) (James, 2016). Among these GM 
crops, proportion of planted acres of biotech soybean, 
corn and cotton were over 90% (Figure 1). Notably, 
the costs of R&D in the seed industry have increased 
speedily, especially in the field of crop seed. New 
technologies based on modern biotechnology and 
changes in intellectual property rights enable 
companies to earn huge profits from developed seeds. 
Therefore, seed selection will continue to be the 
research direction which is primarily interested. A 
special section on new breeding technologies was 
added in 2016 to underline the advancements in 
plant biotechnology using cisgenesis, CRISPR/Cas9, 
zinc finger nuclease technology, synthetic genomics, 
and other techniques that overcome the limitations of 
conventional breeding and recombinant DNA 
technology.  
 According to the United States Department of 
Agriculture (USDA), the total biotech maize planted 
was 35.05 million hectares. The 92% adoption rate 
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was composed of 3% insect resistant (IR), 13% 
herbicide tolerant (HT), and 76% stacked IR/HT 
(James, 2016). Bt corn is a variant of maize that has 
been genetically altered to express one or more 
proteins from the bacterium Bacillus thuringiensis. 
In 1996, the first GM maize producing a Bt Cry 
protein was approved. Agrisure™ RW Rootworm-
Protected Corn contains event MIR604, which 
produced a modified Cry3A (mCry3A) endotoxin 
recreated from B. thuringiensis subsp. tenebrionis 
have enhanced activity against larvae of the western 
corn rootworm and northern corn rootworm (USEPA 
2006). SmartStax™ (Monsanto and Dow 
AgroSciences) was registered as another stacked 
hybrid containing events MON 89034, TC1507, 
MON 88017 and DAS-59122-7 expressing 
Cry1A.105 and Cry2Ab2; Cry1F; Cry3Bb1; and 
Cry34Ab1 and Cry35Ab1 endotoxins, respectively 
(USEPA 2009). It was supposed that Bt hybrids 
exhibit different levels of protection, depending on 
the type of genetic event and promoter used in 
developing a hybrid. Indeed, the genetic event, in 
addition to a promoter, affects the amount, type, and 
location of the production of the endotoxin in the 
plant. Bt hybrids with events Bt11 and MON810, for 
example, provided protection against first and 
second generation European corn borer larvae 
(Ostlie et al., 1997). 
 A corn variety resistant to glyphosate herbicides 
known as “Roundup Ready Corn” was first 
commercialized in 1996 by Monsanto. Afterward, 
Bayer CropScience developed “Liberty Link Corn” 
that is resistant to glufosinate. In 2000, Pioneer Hi-
Bred generated maize which was able to resist to 
imidazolinone herbicides through targeted 
modification of endogenous genes using chimeric 
RNA/DNA oligonucleotides. The results 
demonstrated that oligonucleotide-mediated gene 
manipulation can be applied to crop improvement 
(Zhu et al., 2000). Since the new trait is obtained 
through modifying a gene within its normal 
chromosomal context, position effects, transgene 
silencing, or other concerns that arise as part of 
developing transgenic events are avoided. In 2016, 
MON 87419 with stacked herbicide tolerance 
(glufosinate and dicamba) and MZIR098 with 
glufosinate-resistance and stacked IR (multiple) were 
approved for food, feed and cultivation (ISAAA GM 
Approval Database, 2016). Although glyphosate-
resistant crops have been very successful, the 
evolution of glyphosate-resistant weeds was faster 
and more widespread than expected. Therefore, the 
next wave of technologies will combine resistance to 
glyphosate and other herbicides to provide growers 
with more herbicide options with different mode of 
actions as well as the possibility of using herbicides 
with both foliar and soil residual activity (Green, 
Owen, 2011). 
 Besides that, due to the continued deterioration 
of drought conditions in the south and southeast of 
the US as dry conditions and above average 
temperatures, the total value lost hundreds of million 
dollars. Thus, the approval on December 21, 2011 by 
the USDA of the first generation drought tolerant 
trait for maize, MON87460 provided by the insertion 
of the gene for “cold shock protein B” (cspB) from 
the soil microbe Bacillus subtilis was a timely 
solution to the worsening drought in the US (Federal 
Register, 2011). The drought trait was developed by 
Monsanto in collaboration with BASF Plant Science, 
combining the drought tolerant traits and improved 
hydro efficiency to ensure conservation of soil 
moisture and reduces yield loss under drought 
conditions. DroughtGard™ maize hybrids were 
planted to 1173 million hectares in the US in 2016 - 
equivalent to 45% increase from 2015. As of 
November 2016, US regulators have approved 44 
single maize events since 1996 with insect resistance, 
herbicide tolerance, drought tolerance and stacks 
thereof, for food, feed, and cultivation.  
 The majority of the soybeans grown in the US 
are from seeds that have been enhanced through 
biotechnology. The soybean RReady2YieldTM was 
a representative of the first new generation of GM 
crops and most successful herbicide tolerant 
soybean to be commercialized in the US since 1996 
with 24 GM soybean events approved for food, 
feed, and cultivation by 2016. Roundup Ready® 
soybeans expressed a version of 5-
enolpyruvylshikimate-3-phosphate synthase 
(EPSPS) from the Agrobacterium tumefaciens CP4 
strain, which could survive in a glyphosate 
production facility. The expression is regulated by 
an enhanced 35S promoter (E35S) from cauliflower 
mosaic virus (CaMV), a chloroplast transit peptide 
(CTP4) coding sequence from Petunia hybrida, and 
a nopaline synthase (nos 3') transcriptional 
termination element from A. tumefaciens (Padgette 
et al., 1995). The plasmid with EPSPS and the 
other genetic elements mentioned above was 
inserted into soybean germplasm with a gene gun 
by scientists at Monsanto and Asgrow (Funke et al., 
2006). After this accomplishment, additional 
Journal of Biotechnology 15(4): 589-603, 2017 
597 
varieties with resistance to dicamba and 2,4-D were 
scheduled for release as regulatory approvals are 
obtained, and will form the backbone of weed 
management strategies in the US non-organic 
soybean production, thus helping prolong the 
effectiveness of the current system that mostly 
depends on using glyphosate with glyphosate-
resistant varieties. Beyond herbicide resistance, 
forthcoming varieties will possess value-added 
traits to improve product functionality and health 
benefits. The observation that targeted down-
regulation of FAD2-1A and -1B genes, and SAD 
genes via seed-specific expression of 
posttranscriptional gene-silencing elements could 
increase oleic and stearic soybean oils, respectively 
(Clemente, Cahoon, 2009). Another valuable trait 
of soybean was acquired in soybean seed with low 
phytic acid mutations that both improved human 
absorption of iron and zinc, and also improved 
animal feed that will reduce phosphorus pollution 
(Yuan et al., 2007). 
 Other crops approved for commercialization 
include varieties of flax, papaya, potatoes, radicchio, 
canola, rice, squash, alfalfa, sugar beets, and 
tomatoes. Some of these crops are not 
commercialized or not widely planted. In general, 
even though GM crops provide a number of 
economic and ecological benefits, there are still 
various concerns about their risks to human health. 
Very little of the US commodity crops are sold 
directly to consumers as food. Recent approvals of 
new biotech apples and potatoes have some 
biotechnology supporters hoping new products, with 
traits such as disease resistance or nutrition 
enhancement, will move more quickly through the 
regulatory pipeline. Typically, Yang and colleagues 
engineered the common white button (Agaricus 
bisporus) mushroom to resist browning. The effect 
was achieved by targeting the family of genes that 
encodes polyphenol oxidase (PPO) - an enzyme that 
causes browning. By using the gene-editing tool 
CRISPR/Cas9 to remove just a handful of base pairs 
in the mushroom’s genome, he knocked out one of 
six PPO genes, leading to reduce the enzyme’s 
activity by 30% (Waltz, 2016). The mushroom is one 
of about 30 genetically modified organisms (GMOs) 
to sidestep the USDA regulatory system in the past 
five year, making it the first CRISPR-edited 
organism to receive a green light from the US 
government. Not only mushroom, new varieties of 
corn, tomatoes, and cotton were also developed by 
this technique. Adoption of the CRISPR/Cas9 
technology in plant research would enable the 
investigation of plant biology at an unprecedented 
depth and create innovative applications in precise 
crop breeding. 
 





Biotech area (million ha) 




IR HT IR/HT Other traits Total 
Soybean 33.87 - 31.84 (100%) -  31.84 94 
Maize 38.10 1.14 (3%) 4.95 (13%) 28.96 (76%)  35.05 92 
Cotton 3.98 0.16 (4%) 0.36 (9%) 3.18 (80%)  3.70 93 
Canola 0.69 - 0.62 (100%) -  0.62 90 
Sugar beet 0.47 - 0.47 (100%) -  0.47 100 
Alfalfa 8.46 - 1.21 (98%)  0.02 1.23 14 
Papaya <0.01 - - - <0.01 <0.01 <0.01 
Squash <0.01 - - - <0.01 <0.01 <0.01 
Potato <0.01 - - - <0.01 <0.01 <0.01 
Total 85.60 - - -  72.92 86 









Generation of transgenic animals 
 In the field of agriculture, genetic engineering is 
a potential power not only for generating GM crops 
with novel traits in order to resist diseases, increase 
yield and enhance nutrition, but also for developing 
GM animals and animal products with a goal of drug 
provision. Chymosin, a biotechnology-produced 
enzyme, is used widely in cheese production. Bovine 
somatotropin (BST, also known as “bovine growth 
hormone”) is a naturally occurring protein that can 
be produced in greater quantities through genetic 
technology. The genetically engineered version of 
BST (recombinant BST) was first approved by FDA 
in 1993 (Cowan, 2015). In 2006, the US scientists 
generated cloned transgenic pigs which are rich in 
omega-3 fatty acids. By nuclear transferred a vector 
pCAGGS-hfat-1 containing a humanized 
Caenorhabditis elegans gene, fat-1, encoding an n-3 
fatty acid desaturase into PCFF4-3/pST103 cells, 
hfat-1 transgenic pigs produced high levels of n-3 
fatty acids from n-6 analogs, and their tissues 
reduced a ratio of n-6/n-3 fatty acids significantly 
(Lai et al., 2006). In 2009, FDA approved the first 
product from a transgenic goat, an anticlotting 
protein known as ATryn, for treatment of patients 
with hereditary antithrombin deficiency who are 
undergoing surgical or childbirth procedures. 
Through microinjection of human antithrombin 
genes into the cell nucleus of goats’ embryos, a 
recombinant human antithrombin III protein was 
manufactured in their milk. On November 19, 2015, 
the FDA approved the first GM animal as human 
food, announced that the fast-growing AquAdvatage 
Atlantic Salmon produced by AquaBounty 
Technologies is as safe to eat and nutritious as non-
GM Atlantic salmon. The GM salmon was inserted 
with a growth hormone gene from Chinook salmon 
under the control of a promoter from ocean eelpout 
that permits the salmon to grow at approximately 
twice the rate of a traditional Atlantic salmon 
(Cowan, 2015). After a rigorous evaluation on the 
safety and effectiveness of the GM salmon, the FDA 
concluded that the inserted genes remained stable 
over all generations of fish, therefore the 
modification is safe for the fish and the food derived 
Figure 1. Adoption of genetically modified crops by seed trait in the US in 2005 and 2017 (USDA, Economic Research 
Service using data from the USDA, National Agricultural Statistic Service’s June Agricultural Survey). Data for each crop 
include seed varieties with herbicide tolerance (HT), insect resistance (Bt), or both (Stacked) traits; soybean have only HT 
varieties. 
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therefrom are safe for human and animal  
consumption (Wong, Chan, 2016). 
 The tendencies of future transgenic livestock in 
animal agriculture are to increase sow milk output in 
order to produce faster-growing piglets in swine, to 
develop genetically engineered cattle enabling to 
resist the bacterium that causes mastitis, and to yield 
pharmaceuticals and/or human organ and tissue 
replacements. Application of new gene editing 
techniques is allowing scientists to more easily 
perform cisgenic breeding - genetic manipulation 
without inserting the foreign genes into the host 
genome. Those products face lower regulatory 
hurdles when compared with transgenics, in which 
genes are moved into plants or animals from other 
species. Recently, pigs are capable of deadly porcine 
reproductive and respiratory syndrome virus 
(PRRSV)-resistance through manipulating CD163 
gene by CRISPR/Cas9 technology. The results 
demonstrated a practical means to eliminate PRRSV-
associated reproductive disease, a major source of 
economic hardship to agriculture (Whitworth, 
Prather, 2017; Prather et al., 2017). 
CONCLUSION 
 Research and development in modern 
biotechnology and gene technology in the US are 
always at the forefront in the world. There were lots of 
accomplishments in numerous fields including 
research, medicine, industrial biotechnology and 
agriculture in the past decades. New technologies 
have been permitted restrictedly to apply in clinical 
trials with expectation of curing genetic diseases and 
cancers. GM crops and animals with novel traits have 
also been developed and approved to commercialize 
in the US market. However, due to serious ethical 
regulations and controversy regarding to human health 
and environment, limitations of research subjects and 
applied techniques are still challenges for scientists in 
the US and worldwide. The US government has 
developed suitable policies and continues to invest in 
order to promote science and technology, and improve 
the quality of human life. 
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